Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
Orally bioavailable KAT6A degraders demonstrated potent antiproliferative activity in diverse in vivo models of ER+/HER2- breast cancer KAT6A degradation was active in both ESR1-mutant and wild-type cell models Degraders were well-tolerated in all groups SAN FRANCISCO, Nov.